Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neurofibromatosis 1 2Neurofibroma 2Neurofibromatoses 1Neurofibroma, Plexiform 1Colorectal Neoplasms 1Breast Neoplasms 1Advanced Solid Tumor 1Advanced Cancer 1

Interventions

ulixertinib 1tislelizumab 1talazoparib 1serabelisib 1sapanisertib 1pembrolizumab 1olaparib 1mirdametinib 1lenvatinib 1erdafitinib 1crenigacestat 1atezolizumab 1Ramucirumab 1Paclitaxel 1PM 01183 1Injections 1IFL protocol 1Gemcitabine 1Bosentan 1BID protein, human 1Appointments and Schedules 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumor × mirdametinib × Clear all
NCT05580770 2026-05-01

Mirdametinib + BGB-3245 in Advanced Solid Tumors

SpringWorks Therapeutics, Inc.

Phase 1/2 Terminated
23 enrolled 22 charts
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡